Racial Disparities in Heart Disease Mortality in the 50 Largest U.S. Cities

Maureen R Benjamins1,2, Jana L Hirschtick3, Bijou R Hunt1

  • 1Sinai Urban Health Institute, Sinai Health System, Mount Sinai Hospital, 1500 S. Fairfield Ave, Rm K443, Chicago, IL, 60608, USA.

Insights

Heart disease mortality disproportionately affects Black Americans, with significant racial disparities evident even at the city level. Addressing these disparities requires targeted interventions based on local data and socioeconomic factors.

Area of Science:

  • Public Health
  • Epidemiology
  • Health Equity

Background:

  • Heart disease is the leading cause of death in the U.S.
  • It significantly contributes to racial disparities in life expectancy.
  • City-level data on heart disease mortality and racial disparities are lacking.

Purpose of the Study:

  • To calculate age-adjusted heart disease mortality rates and racial disparities for non-Hispanic Black and White populations.
  • To analyze trends in these disparities from 1990-1994 to 2005-2009 for the U.S. and 50 largest cities.
  • To examine the relationship between racial disparities in heart disease mortality and city-level socioeconomic indicators.

Main Methods:

  • Calculated age-adjusted mortality rates, rate ratios (RRs), and rate differences (RDs) for Black and White populations.
  • Analyzed data for two time periods: 1990-1994 and 2005-2009.
  • Correlated disparities with city-level income inequality and median household income.

Main Results:

  • Nationally, Black individuals had significantly higher heart disease mortality rates than White individuals in both periods.
  • Disparities increased over time in 11 cities due to larger rate improvements among Whites.
  • An estimated 19,448 excess Black deaths occurred annually in the U.S.
  • City income inequality and median household income were associated with disparities.

Conclusions:

  • City-specific heart disease mortality data are crucial for addressing health inequities.
  • Socioeconomic factors like income inequality play a role in racial disparities in heart disease.
  • Targeted public health interventions can help reduce heart disease morbidity and mortality among minority populations.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
790
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K